republic-os/legislation/us/states/va/2025/hb-1641.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	State plan for medical assistance services and health insurance; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.	State plan for medical assistance services and health insurance; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Directs the Board of Medical Assistance Services to amend the state plan for medical assistance services to include a provision for payment of medical assistance for the prophylaxis, diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) that includes payment for treatment using antimicrobials, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.The bill also requires each insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis; each corporation providing individual or group accident and sickness subscription contracts; and each health maintenance organization providing a health care plan for health care services to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS and PANS. The bill requires such coverage to include coverage for treatment using antimicrobials, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.The bill prohibits an insurer, corporation, or organization from (i) denying or delaying the coverage of PANDAS or PANS because the enrollee previously received treatment or because the enrollee was diagnosed with or received treatment for his condition under a different diagnostic name, including autoimmune encephalopathy; (ii) limiting coverage of immunomodulating therapies for the treatment of PANDAS or PANS in a manner that is inconsistent with the treatment guidelines developed by a consortium convened for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of PANDAS or PANS that are accessible for medical professionals and are based on evidence of positive patient outcomes; (iii) requiring a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies for the treatment of PANDAS or PANS; or (iv) denying coverage for out-of-state treatment if the service is not available within the Commonwealth. This bill is a recommendation of the Health Insurance Reform Commission.	us/states/va	Virginia General Assembly	2025	HB 1641	Virginia HB 1641 (2025)	bill		enacted	Patrick A. Hope	3	32	10	2025-01-03	2025-03-18	openstates	ocd-bill/633a0c1c-a368-47e6-bc3c-fda1c971fbab	https://lis.virginia.gov/bill-details/20251/HB1641	764052d5f8bc418d3c0bc5556e5bc71fd0deb58204ab7626ca2b05de7e844d27	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-va

Virginia HB 1641 (2025) — State plan for medical assistance services and health insurance; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.

State plan for medical assistance services and health insurance; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Directs the Board of Medical Assistance Services to amend the state plan for medical assistance services to include a provision for payment of medical assistance for the prophylaxis, diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) that includes payment for treatment using antimicrobials, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.The bill also requires each insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis; each corporation providing individual or group accident and sickness subscription contracts; and each health maintenance organization providing a health care plan for health care services to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS and PANS. The bill requires such coverage to include coverage for treatment using antimicrobials, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.The bill prohibits an insurer, corporation, or organization from (i) denying or delaying the coverage of PANDAS or PANS because the enrollee previously received treatment or because the enrollee was diagnosed with or received treatment for his condition under a different diagnostic name, including autoimmune encephalopathy; (ii) limiting coverage of immunomodulating therapies for the treatment of PANDAS or PANS in a manner that is inconsistent with the treatment guidelines developed by a consortium convened for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of PANDAS or PANS that are accessible for medical professionals and are based on evidence of positive patient outcomes; (iii) requiring a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies for the treatment of PANDAS or PANS; or (iv) denying coverage for out-of-state treatment if the service is not available within the Commonwealth. This bill is a recommendation of the Health Insurance Reform Commission.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Introduced (filed) — source
2. Chaptered (committee substitute) — source
3. Enrolled (enrolled) — source

Votes

• Reported from Appropriations (22-Y 0-N) — 22–0 (pass) · lower
• Reported from Labor and Commerce and rereferred to Appropriations (22-Y 0-N) — 22–0 (pass) · lower
• Passed House (99-Y 0-N) — 99–0 (pass) · lower
• Reported from Finance and Appropriations (14-Y 0-N) — 14–0 (pass) · upper
• Constitutional reading dispensed (on 2nd reading) (39-Y 0-N) — 39–0 (pass) · upper
• Passed Senate (40-Y 0-N) — 40–0 (pass) · upper
• Subcommittee recommends reporting and referred to Appropriations (7-Y 0-N) — 7–0 (pass) · lower
• Reported from Commerce and Labor and rereferred to Finance and Appropriations (15-Y 0-N) — 15–0 (pass) · upper
• Subcommittee recommends reporting (6-Y 0-N) — 6–0 (pass) · lower
• Read third time and passed House (97-Y 0-N) — 97–0 (pass) · lower

Sponsors

• Patrick A. Hope — primary (person)
• Adele Y. McClure — cosponsor (person)
• Barbara A. Favola — cosponsor (person)
• Betsy B. Carr — cosponsor (person)
• Bonita G. Anthony — cosponsor (person)
• Chris Obenshain — cosponsor (person)
• Debra D. Gardner — cosponsor (person)
• Destiny LeVere Bolling — cosponsor (person)
• Elizabeth B. Bennett-Parker — cosponsor (person)
• Ghazala F. Hashmi — cosponsor (person)
• Holly M. Seibold — cosponsor (person)
• Irene Shin — cosponsor (person)
• Jennifer B. Boysko — cosponsor (person)
• Joseph P. McNamara — cosponsor (person)
• Joshua G. Cole — cosponsor (person)
• Karen Keys-Gamarra — cosponsor (person)
• Katrina Callsen — cosponsor (person)
• Kelly K. Convirs-Fowler — cosponsor (person)
• Lamont Bagby — cosponsor (person)
• Laura Jane Cohen — cosponsor (person)
• Mark D. Sickles — cosponsor (person)
• Marty Martinez — cosponsor (person)
• Michael B. Feggans — cosponsor (person)
• Michael J. Jones — cosponsor (person)
• Michelle Lopes Maldonado — cosponsor (person)
• Nadarius E. Clark — cosponsor (person)
• Paul E. Krizek — cosponsor (person)
• R. Creigh Deeds — cosponsor (person)
• R. Lee Ware — cosponsor (person)
• Rae Cousins — cosponsor (person)
• Richard C. "Rip" Sullivan, Jr. — cosponsor (person)
• Rodney T. Willett — cosponsor (person)
• Rozia A. Henson, Jr. — cosponsor (person)
• Russet Perry — cosponsor (person)
• Saddam Azlan Salim — cosponsor (person)
• Sam Rasoul — cosponsor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2025-01-03 Prefiled and ordered printed; Offered 01-08-2025 25101763D filing, introduction
• 2025-01-03 Referred to Committee on Labor and Commerce referral-committee
• 2025-01-10 Assigned L & C sub: Subcommittee #1 referral-committee
• 2025-01-14 Subcommittee recommends reporting and referred to Appropriations (7-Y 0-N)
• 2025-01-16 Reported from Labor and Commerce and referred to Appropriations (22-Y 0-N) committee-passage
• 2025-01-17 Assigned Approps sub: Health & Human Resources referral-committee
• 2025-01-22 Fiscal Impact Statement from Department of Planning and Budget (HB1641)
• 2025-01-29 Subcommittee recommends reporting (6-Y 0-N)
• 2025-01-31 Reported from Appropriations (22-Y 0-N) committee-passage
• 2025-02-02 Read first time reading-1
• 2025-02-03 Read second time and engrossed reading-2
• 2025-02-04 Read third time and passed House (97-Y 0-N) passage, reading-3
• 2025-02-04 Reconsideration of passage agreed to by House
• 2025-02-04 Passed House (99-Y 0-N) passage
• 2025-02-05 Constitutional reading dispensed (on 1st reading)
• 2025-02-05 Referred to Committee on Commerce and Labor referral-committee
• 2025-02-10 Reported from Commerce and Labor and rereferred to Finance and Appropriations (15-Y 0-N) committee-passage
• 2025-02-14 Reported from Finance and Appropriations (14-Y 0-N) committee-passage
• 2025-02-17 Rules suspended
• 2025-02-17 Constitutional reading dispensed (on 2nd reading) (39-Y 0-N)
• 2025-02-17 Passed by for the day
• 2025-02-18 Read third time reading-3
• 2025-02-18 Passed Senate (40-Y 0-N) passage
• 2025-03-07 Enrolled enrolled
• 2025-03-07 Bill text as passed House and Senate (HB1641ER) passage
• 2025-03-07 Fiscal Impact Statement from Department of Planning and Budget (HB1641)
• 2025-03-07 Signed by Speaker passage
• 2025-03-10 Signed by President passage
• 2025-03-11 Enrolled Bill communicated to Governor on (date) enrolled, executive-receipt
• 2025-03-11 Governor's Action Deadline 11:59 p.m., March 24, 2025 executive-receipt
• 2025-03-18 Approved by Governor-Chapter 8 (Effective 07/01/25) executive-signature
• 2025-03-18 Acts of Assembly Chapter text (CHAP0008)

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/633a0c1c-a368-47e6-bc3c-fda1c971fbab. Confidence: reported (aggregated from official Virginia legislature records).